Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology

BJU Int. 2018 May;121(5):703-715. doi: 10.1111/bju.14091. Epub 2018 Jan 8.

Abstract

To establish a set of consensus statements to facilitate physician management strategies for patients with metastatic prostate cancer (mPCa) in Hong Kong. A local expert consensus was organized jointly by the two main professional organizations representing prostate cancer specialists in Hong Kong. A total of 12 experts were included in the consensus panel. Six of the most crucial and relevant areas of debate regarding the management of mPCa were identified. With the use of a modified Delphi method, several panel meetings were held for the members to discuss their clinical experience and the published literature relevant to the areas of debate. At the final meeting, each drafted statement was voted on by every member based on its practicability of recommendation in the locality. After the panel voting, a total of 45 consensus statements regarding the management of mPCa were ultimately accepted and established. The consensus statements were primarily derived from the latest clinical evidence and major overseas guidelines, with the consideration of local clinical experience and practicability. These are considered applicable recommendations for Hong Kong physicians for the management of mPCa patients.

Keywords: #PCSM; #ProstateCancer; castration-naïve prostate cancer; castration-resistant prostate cancer; consensus; metastatic prostate cancer.

Publication types

  • Consensus Development Conference
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Disease Management
  • Gene Expression Regulation, Neoplastic
  • Hong Kong
  • Humans
  • Male
  • Neoplasm Metastasis / pathology*
  • Neoplasm Metastasis / therapy*
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians'
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy*
  • Survival Rate
  • Urology*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Biomarkers, Tumor